Registry of deep vein thrombosis patients hospitalized at the Department of Vascular Diseases, University Hospital Centre Zagreb

    Authors

    Keywords

    deep vein thrombosis, registry, novel oral anticoagulants, low molecular weight heparin, warfarin

    DOI

    https://doi.org/10.15836/ccar2018.450

    Full Text

    Registry “Deep vein thrombosis” includes and evaluates all patients with deep vein thrombosis (DVT) treated at the Department of Vascular Diseases, University Hospital Centre Zagreb from 1 st January 2016. The results of the registry will be presented as compared to the results presented at the 11 th Congress of Croatian Cardiology Society ( 1 ), which were related to the pilot project in the period of 1 st January until 1 st October 2016. The registry includes a total of 305 patients. Parameters covered by the registry relate to the etiology of venous thrombosis, disease localization, complications during treatment, treatment in the acute phase and in the advanced treatment phase. Out of the total data, we highlight an increase of the patients with venous thrombosis related by a surgical procedure (8.8%). In the total population incidence of venous thrombosis after the previous surgical procedure was 23%. The initial treatment of DVT in the acute phase ( Figure 1 ) increased significantly in favor of the use of novel oral anticoagulants (NOAC) (15.5%) because in the first 10 months of the pilot project all patients were treated with low molecular weight heparin (LMWH) and warfarin, while in the past 2 years this number was reduced. In the prolonged treatment ( Figure 2 ) the use of LMWH increased by 12.2%, the use of NOAC by 27.4%, while the application of the standard treatment method to warfarin recorded a decline of 39.6%. The occurrence of bleeding is reduced by 3%. Treatment options during 2016 compared with 2016-2018 in the acute phase of treatment. NOAC = novel oral anticoagulants; LMWH = low molecular weight heparin. Treatment options during 2016 compared withj 2016-2018 in the extended treatment. LMWH = low molecular weight heparin; NOAC = novel oral anticoagulants; standard th. = standard therapy. In the period of 2 years, the method of treating venous thrombosis has significantly changed in favor of treatment with new oral anticoagulants, resulting in an increase in the number of outpatient treatment by 15.5%, with a decrease in the occurrence of bleeding by 3%.

    Cardiologia Croatica
    Back to search

    Registry of deep vein thrombosis patients hospitalized at the Department of Vascular Diseases, University Hospital Centre Zagreb

    Extended Abstract
    Issue11-12
    Published
    Pages450-451
    PDF via DOIhttps://doi.org/10.15836/ccar2018.450
    deep vein thrombosis
    registry
    novel oral anticoagulants
    low molecular weight heparin
    warfarin

    Authors

    Ljiljana BanfićORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Majda Vrkić KirhmajerORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Mislav PuljevićORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Zoran Miovski*ORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Krešimir PutarekORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Marijan PašalićORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia

    Full Text

    Registry “Deep vein thrombosis” includes and evaluates all patients with deep vein thrombosis (DVT) treated at the Department of Vascular Diseases, University Hospital Centre Zagreb from 1 st January 2016. The results of the registry will be presented as compared to the results presented at the 11 th Congress of Croatian Cardiology Society ( 1 ), which were related to the pilot project in the period of 1 st January until 1 st October 2016. The registry includes a total of 305 patients. Parameters covered by the registry relate to the etiology of venous thrombosis, disease localization, complications during treatment, treatment in the acute phase and in the advanced treatment phase. Out of the total data, we highlight an increase of the patients with venous thrombosis related by a surgical procedure (8.8%). In the total population incidence of venous thrombosis after the previous surgical procedure was 23%. The initial treatment of DVT in the acute phase ( Figure 1 ) increased significantly in favor of the use of novel oral anticoagulants (NOAC) (15.5%) because in the first 10 months of the pilot project all patients were treated with low molecular weight heparin (LMWH) and warfarin, while in the past 2 years this number was reduced. In the prolonged treatment ( Figure 2 ) the use of LMWH increased by 12.2%, the use of NOAC by 27.4%, while the application of the standard treatment method to warfarin recorded a decline of 39.6%. The occurrence of bleeding is reduced by 3%. Treatment options during 2016 compared with 2016-2018 in the acute phase of treatment. NOAC = novel oral anticoagulants; LMWH = low molecular weight heparin. Treatment options during 2016 compared withj 2016-2018 in the extended treatment. LMWH = low molecular weight heparin; NOAC = novel oral anticoagulants; standard th. = standard therapy. In the period of 2 years, the method of treating venous thrombosis has significantly changed in favor of treatment with new oral anticoagulants, resulting in an increase in the number of outpatient treatment by 15.5%, with a decrease in the occurrence of bleeding by 3%.